Please provide your email address to receive an email when new articles are posted on . PHOENIX — In this video, Mazen Noureddin, MD, MHSc, professor of medicine at Houston Methodist, highlights ...
After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease ...
Metabolic dysfunction-associated steatohepatitis, or MASH, is a disease at the intersection of metabolic and hepatic dysfunction — creating a complex clinical picture for people living with this ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic dysfunction-associated steatohepatitis (MASH): Moderator Sobia Laique, MD, of the Cleveland ...
The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions. By the end of this ...
The paper published in Journal of Hepatology demonstrates that NIS2+™ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH 1 clinical ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results